NCT01797575View on ClinicalTrials.gov

N-Acetyl Cysteine and Aspirin as an Adjunctive Treatment for Bipolar Disorder

PHASE2CompletedINTERVENTIONAL
Enrollment

38

Participants

Timeline

Start Date

January 31, 2013

Primary Completion Date

February 1, 2017

Study Completion Date

February 1, 2017

Conditions
Bipolar Disorder
Interventions
DRUG

Aspirin

aspirin 1000mg (2 capsules of 500mg) every morning in addition to his/her antidepressant and/or mood stabilizer medicine

DIETARY_SUPPLEMENT

N-acetyl-cysteine (NAC)

taking N-acetyl-cysteine (NAC) 1000mg (2 capsules of 500mg) two times a day in addition to his/her antidepressant and/or mood stabilizer medicine

DRUG

Sugar Pill

research subject will be taking placebo in addition to his/her antidepressant and/or mood stabilizer medicine

Trial Locations (1)

77054

UT Center of Excellence on Mood Disorders, Houston

All Listed Sponsors
collaborator

Stanley Medical Research Institute

OTHER

lead

The University of Texas Health Science Center, Houston

OTHER

NCT01797575 - N-Acetyl Cysteine and Aspirin as an Adjunctive Treatment for Bipolar Disorder | Biotech Hunter | Biotech Hunter